A prolonged suppression of endogenous parathyroid hormone was observed in the study. Credit: Nephron / Wikimedia.

Extend Biosciences has reported positive results from its first-in-human Phase I clinical trial of EXT608 for the treatment of hypoparathyroidism, a chronic, rare endocrine disorder.

The ongoing, placebo-controlled, randomised, double-blind study divided 24 healthy subjects into six treatment groups to receive a single ascending dose of EXT608 subcutaneously.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Interim data analysis showed that EXT608 was safe and well tolerated with no serious adverse events.

The study also demonstrated a dose-dependent increase in serum calcium, without a concomitant increase in urinary calcium.

As anticipated, prolonged suppression of endogenous parathyroid hormone was also observed in the study.

See Also:

EXT608 can also be effective when given once a week, as suggested in early pharmacokinetic analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ExtendBio co-founder and CEO Tarik Soliman said: “The data not only demonstrate that EXT608 is safe and well-tolerated, but they also show the potential for the compound to replace PTH for an extended period of time, which would result in increased patient adherence and improved quality of life.

“EXT608 has the potential to be a promising solution for physicians and patients seeking a convenient treatment option to effectively manage this debilitating disease.

“We look forward to rapidly advancing EXT608 into the next phase of clinical study.”

EXT608 is developed using the company’s D-VITylation platform and upon injection, it is fully active at the PTH receptor.

The company intends to make the treatment available for patients in a simple, easy-to-use single-use disposable syringe.